Breast Cancer Liquid Biopsy Market By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs)), By Application (Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Breast Cancer Liquid Biopsy Market was valued at USD 1.1 billion in 2023 and will surpass USD 2.9 billion by 2030; growing at a CAGR of 14.7% during 2024 - 2030.

The breast cancer liquid biopsy market is rapidly expanding as non-invasive testing methods gain prominence in the detection and management of breast cancer. Liquid biopsy is an advanced technology that involves analyzing blood or other bodily fluids for biomarkers indicative of cancer, offering an alternative to traditional tissue biopsy. This approach provides numerous benefits, including reduced patient discomfort, quicker recovery times, and the ability to conduct repeated tests to monitor disease progression. With advancements in molecular diagnostics, liquid biopsy is poised to revolutionize breast cancer screening, diagnosis, and treatment by enabling more precise, real-time monitoring of tumor dynamics.

The rising prevalence of breast cancer and the growing demand for early detection and personalized treatment are key drivers behind the expansion of this market. Liquid biopsy enables the detection of minimal residual disease and recurrence at an earlier stage, facilitating timely intervention and better patient outcomes. With the advent of new biomarker technologies, the breast cancer liquid biopsy market is attracting substantial investment from both healthcare providers and biotechnology firms, making it one of the most promising areas in oncology research. The use of circulating biomarkers, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs), is expected to enhance the precision and reliability of liquid biopsies in breast cancer management.

Circulating Tumor Cells (CTCs) Segment is Leading the Market

Among the various circulating biomarkers used in liquid biopsy, circulating tumor cells (CTCs) represent the largest and most established segment. CTCs are cancer cells that have shed from the primary tumor and enter the bloodstream, providing a valuable insight into the metastatic process of breast cancer. These cells can be isolated and analyzed to assess the genetic makeup of the tumor, detect early signs of metastasis, and monitor treatment efficacy. The ability to track CTCs in real-time has made them a key tool in both early detection and ongoing monitoring of breast cancer patients.

The growth of the CTCs segment is primarily attributed to advancements in technology that allow for the sensitive and accurate capture of these cells from blood samples. Techniques like microfluidics and immunoassays have improved the efficiency of CTC isolation, making it feasible to detect even a small number of CTCs in a patient's bloodstream. As a result, CTCs are becoming a cornerstone in personalized medicine, allowing oncologists to select the most appropriate treatment options based on the tumor’s genetic profile. Furthermore, the non-invasive nature of CTC testing, along with its ability to provide real-time information, positions it as a critical component in the future of breast cancer management, driving its dominance in the liquid biopsy market.

Early Detection/Screening is the Fastest Growing Application

The early detection and screening of breast cancer using liquid biopsy are gaining significant momentum and are poised to be the fastest-growing application in this market. Early detection is critical in improving breast cancer survival rates, as the prognosis is much more favorable when the disease is identified at an early stage. Liquid biopsy, which offers the potential to detect cancer biomarkers long before clinical symptoms appear, is an attractive alternative to traditional screening methods like mammography. The ability to perform frequent and non-invasive tests also enables better monitoring of high-risk individuals and those with a family history of breast cancer.

The growing focus on early detection is fueled by the increasing awareness of breast cancer and the need for more efficient, less invasive diagnostic tools. With ongoing research into the biomarkers that indicate the earliest stages of breast cancer, liquid biopsy is becoming more effective in identifying patients at risk before the onset of symptoms. As liquid biopsy technologies continue to improve in sensitivity and specificity, they are expected to play a pivotal role in widespread breast cancer screening, offering significant advantages over traditional methods in terms of patient comfort and diagnostic speed. This growth in early detection and screening is expected to drive the market's expansion, particularly in regions with high breast cancer incidence rates.

North America Leads the Breast Cancer Liquid Biopsy Market

North America is the largest region for the breast cancer liquid biopsy market, driven by the well-established healthcare infrastructure, high cancer awareness, and significant research and development investments in biotechnology. The United States, in particular, is at the forefront of advancements in liquid biopsy technology, with numerous companies and academic institutions focusing on the development and commercialization of innovative diagnostic solutions. The increasing adoption of non-invasive diagnostic methods in the region is supported by strong reimbursement policies, which have made liquid biopsy tests more accessible to a larger patient population.

Moreover, North America's regulatory environment, with agencies like the U.S. Food and Drug Administration (FDA) offering approval pathways for liquid biopsy products, has further accelerated the market's growth. The rising incidence of breast cancer in North America, coupled with the demand for personalized and precision medicine, is expected to drive the continuous expansion of the liquid biopsy market. North America is also experiencing an increase in public-private partnerships aimed at advancing cancer research, which will likely contribute to the region’s dominant position in the market for years to come.

Competitive Landscape: Key Players and Market Trends

The breast cancer liquid biopsy market is characterized by a competitive landscape with several leading companies driving innovation and market growth. Major players in this market include Guardant Health, Biocept, Thermo Fisher Scientific, Foundation Medicine, and Illumina. These companies are focused on developing and commercializing advanced liquid biopsy technologies that enable the detection of breast cancer at earlier stages and provide more accurate, real-time monitoring of disease progression.

The competitive environment is shaped by continuous technological advancements, including improvements in biomarker discovery, CTC isolation techniques, and the development of comprehensive panels that assess multiple genetic mutations at once. As the demand for non-invasive cancer diagnostics continues to rise, companies are also focusing on expanding their product offerings and enhancing the sensitivity and specificity of their tests. Strategic partnerships, mergers, and acquisitions are common in this market, as companies seek to consolidate resources, enhance research capabilities, and expand their market reach. With significant investments in research and development, the breast cancer liquid biopsy market is expected to experience further innovation and growth in the coming years.

Recent Developments:

• In February 2024, Guardant Health launched an innovative liquid biopsy test specifically for breast cancer, aimed at improving early detection and personalized treatment options.
• In January 2024, Thermo Fisher Scientific acquired a liquid biopsy startup focused on breast cancer diagnostics, expanding its product offerings in the cancer detection market.
• In December 2023, Biocept, Inc. announced positive results from a clinical trial using its liquid biopsy platform to monitor breast cancer patients undergoing treatment, showing improved outcomes in early-stage detection.
• In November 2023, Liquid Biopsy Diagnostics entered into a partnership with leading research hospitals to enhance the development and clinical validation of liquid biopsy tests for breast cancer screening.
• In October 2023, Natera, Inc. expanded its liquid biopsy portfolio with the introduction of a new product designed to detect breast cancer recurrence, offering a non-invasive monitoring solution for patients.

List of Leading Companies:

• The Menarini Group
• NeoGenomics Laboratories
• F. Hoffmann - La Roche Ltd.
• Myriad Genetics, Inc.
• Thermo Fisher Scientific, Inc.
• QIAGEN
• Biocept, Inc.
• Sysmex Corporation
• Fluxion Biosciences, Inc.
• Epic Sciences, Inc.

Report Scope: